Development of Gut Microbiome-based Therapeutics for IBD

Gut microbial composition (dysbiosis) and breakdown of immune tolerance to commensal gut bacteria are primary factors in the pathogenesis of inflammatory bowel disease (IBD). Ongoing and promises of novel microbiota-based therapy development have generated a great deal of interest for potential IBD treatment. Microbiota-based therapeutics such as antibiotics, prebiotics/probiotics/synbiotics and faecal microbial transplant (FMT) are hypothesised to be safe and have the potential to rectify the dysbiosis driving the dysregulated immune response.

Fig. 1. Current microbiome-based therapeutic strategies in IBD. (Hu, et al., 2024)

Our Microbiota-based Therapy Development Services

With its roots in investigating the cause of IBD and a dedicated team that includes the most experienced researchers in the field of the microbiome, Ace Therapeutics is a specialist company in developing microbiome-based therapies. Your research is enhanced by the interdisciplinary expertise of our experts and receives unique guidance at every stage of the development process.

These studies include gut microbiome characterization, metabolomic analysis, and preclinical study design, all tailored to our clients needs.

Antibiotic Therapy R&D Services

At Ace Therapeutics, we specialize in comprehensive research and development services focused on antibiotic therapy. Our mission is to provide innovative solutions for the development of IBD therapies by effectively reducing the concentration of bacteria in the intestinal lumen and altering the composition of the intestinal microbiota.

Probiotic Therapy R&D Services

By combining in vitro and in vivo models, we help our clients select strains with both anti-inflammatory potential as well as a capacity to restore the gut epithelial barrier. We are dedicated to assisting our clients in developing genetically modified bacteria as innovative therapies for the treatment of IBD. These engineered bacteria have the potential to modulate intestinal dysbiosis while delivering therapeutically active molecules directly into the gut.

Fecal Microbiota Transplantation Development Services

Ace Therapeutics is dedicated to providing FMT services to help our clients explore the role of gut microbiota in mediating the effects of FMT on colitis. Our expertise enables us to evaluate the protective effects of FMT in animal models of IBD and to identify the associated gut microbiota and intestinal mucosal immune signaling pathway. Our services provide a comprehensive understanding of the mechanisms underlying FMT, enabling our clients to better explain and exploit its therapeutic potential.

Why Choose US

We work with a diverse team of microbiome, immunology and gastroenterology experts with a deep background in developing drugs.
From screening and preclinical efficacy evaluation to the designing of drug delivery systems, we do everything you need for early and efficient development to maximize the chance of success.
A combination of sophisticated technologies including metagenome sequencing and bioinformatics analysis tools, can be used to identify variations in its composition and role, and design treatments by identifying potential targets..

Ace Therapeutics will provide you with advanced scientific support and tailored solutions to increase the speed with which you develop microbiome-based therapies. To learn more, please contact us.

Reference

Hu, K. A., & Gubatan, J. (2023). Gut microbiome-based therapeutics in inflammatory bowel disease. Clinical and Translational Discovery, 3(2), e182.

! For research use only, not intended for any clinical use.